Recurrent Gallbladder Cancer
15
0
0
9
Key Insights
Highlights
Success Rate
64% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
33.3%
5 terminated out of 15 trials
64.3%
-22.2% vs benchmark
7%
1 trials in Phase 3/4
67%
6 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (15)
Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors
BMS-247550 in Treating Patients With Liver or Gallbladder Cancer
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma